Cargando…
PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
Autores principales: | Sharma, Gaurav, Ojha, Rani, Noguera-Ortega, Estela, Rebecca, Vito W., Attanasio, John, Liu, Shujing, Piao, Shengfu, Lee, Jennifer J., Nicastri, Michael C., Harper, Sandra L., Ronghe, Amruta, Jain, Vaibhav, Winkler, Jeffrey D., Speicher, David W., Mastio, Jerome, Gimotty, Phyllis A., Xu, Xiaowei, Wherry, E. John, Gabrilovich, Dmitry I., Amaravadi, Ravi K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744257/ https://www.ncbi.nlm.nih.gov/pubmed/36278493 http://dx.doi.org/10.1172/jci.insight.165688 |
Ejemplares similares
-
PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma
por: Sharma, Gaurav, et al.
Publicado: (2020) -
Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells
por: Nicastri, Michael C., et al.
Publicado: (2017) -
PPT-DB: the protein property prediction and testing database
por: Wishart, David S., et al.
Publicado: (2008) -
Combining Electrochemiluminescence Detection with Aptamer‐Gated Indicator Releasing Mesoporous Nanoparticles Enables ppt Sensitivity for Strip‐Based Rapid Tests
por: Climent, Estela, et al.
Publicado: (2021) -
High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
por: Xu, Jianjun, et al.
Publicado: (2022)